Escitalopram: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [checked revision] |
MDElliottMD (talk | contribs) Expand stub to full MedTemplate parameter set |
MDElliottMD (talk | contribs) parser-claude: Escitalopram MedTemplate refill, Top 300 stub upgrade |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic | | generic = Escitalopram | ||
| brand | | brand = Lexapro | ||
| structure | | structure = | ||
| classes | | classes = [[:Category:SSRIs|Selective serotonin reuptake inhibitor (SSRI)]], [[:Category:Antidepressants|Antidepressant]], [[:Category:Anxiolytics|Anxiolytic]] | ||
| | | uses = <vote slug="major-depressive-disorder-use">Major depressive disorder (FDA, ages 12+)</vote>, <vote slug="generalized-anxiety-disorder-use">Generalized anxiety disorder (FDA, adult)</vote>, <vote slug="panic-disorder-use">Panic disorder (off-label)</vote>, <vote slug="ocd-use">Obsessive-compulsive disorder (off-label)</vote>, <vote slug="ptsd-use">Posttraumatic stress disorder (off-label)</vote>, <vote slug="premenstrual-dysphoric-disorder-use">Premenstrual dysphoric disorder (off-label)</vote>, <vote slug="menopausal-vasomotor-use">Menopausal vasomotor symptoms (off-label)</vote> | ||
| uses | | starting_dose = 10 mg PO once daily; titrate to 20 mg/day after 1-2 weeks if needed | ||
| preparations = Tablets 5, 10, 20 mg; oral solution 1 mg/mL | |||
| fda_max = 20 mg/day (adult); 10 mg/day in elderly and in hepatic impairment | |||
| pill_id = | |||
| routes = Oral | |||
| onset = Antidepressant effect emerges over 1-2 weeks; full clinical effect 4-6 weeks | |||
| duration = 24 hours (once-daily dosing) | |||
| halflife = 27-32 hours<ref name="lexapro-label">FDA Prescribing Information, Lexapro (escitalopram oxalate), AbbVie/Allergan, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021323s047lbl.pdf</ref> | |||
| | | bioavailability = ~80% (oral)<ref name="lexapro-label" /> | ||
| | | pregnancy = Observational signal for persistent pulmonary hypertension of the newborn (small absolute risk) and neonatal adaptation syndrome with third-trimester exposure; weigh against the risks of untreated maternal depression.{{citation needed}} | ||
| | | legal = [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults<ref name="lexapro-label" /> | ||
| | | mechanism = <vote slug="escitalopram-mech-claim">Highly selective serotonin reuptake inhibitor. Escitalopram is the (S)-enantiomer of citalopram, which carries essentially all of the serotonin transporter (SERT) binding activity; the (R)-enantiomer contributes little SERT activity and may carry the QT-prolonging liability that prompted the FDA's 2011 citalopram dose ceiling, giving escitalopram a more favorable QT profile.</vote> CYP2C19 + CYP3A4 metabolism, with CPIC PGx guidance: poor CYP2C19 metabolizers have ~3-fold higher exposure and benefit from a lower starting dose; ultrarapid metabolizers may have inadequate response<ref name="cpic-ssri">CPIC Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors, 2023. https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/</ref>. | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
}} | }} | ||
== References == | |||
<references /> | |||
[[Category:SSRIs]] | |||
[[Category:Antidepressants]] | [[Category:Antidepressants]] | ||
[[Category:Anxiolytics]] | |||